Menu
Content/Inhalt
Home
|
Careers
|
Contact us
Search
Welcome
At a glance
Social responsibility
Our companies
Business Model
Development capabilites
Partnering
Pipeline
Commercial Products
News & Events
Press Releases
Awards
Publications
Conferences
News
27.04.2010
Debiopharm Group™ starts Phase I clinical trial with Debio 0932
26.04.2010
Two New Tenants for EPFL’s Innovation Square
Home
News & Events
Press Releases
PRESS RELEASES
Order
Date asc
Date desc
Title asc
Title desc
Ordering
Display #
5
10
15
20
25
30
50
Date
Item Title
19-Jan-2004
ELOXATIN™ submitted in the United States and in Europe for the adjuvant treatment of patients with colon cancer
11-Jan-2004
Eloxatin™ (oxaliplatin for injection) approved in the United States for the 1st line treatment of metastatic colorectal cancer
07-Jan-2004
ELOXATIN® is becoming a cornerstone therapy for the treatment of metastatic colorectal cancer in Europe
27-Aug-2002
Debiopharm extends its collaboration with Sanofi-Synthélabo on Eloxatin®
19-Aug-2002
Media Alert: successful registration after shortest ever review by the FDA of Eloxatin
< Prev
1
2
Next >
Results 6 - 10 of 10
Tremelimumab - codevelopment with Pfizer Inc
( 1 items )
Debio 0931
( 1 items )
Debio 0932
( 2 items )
Debio 0930
( 1 items )
Debio 0929
( 1 items )
Debio 0928
( 1 items )
Debio 0827
( 1 items )
Debio 0826
( 1 items )
Triptorelin – Trelstar® – Decapeptyl® - Pamorelin®
( 14 items )
Debio 8609 Sanvar®
( 13 items )
Debio 025
( 9 items )
Debio 9902 - ZT-1
( 9 items )
Debio 0614 (istaroxime)
( 2 items )
Debio 0507
( 3 items )
Debio 0719
( 1 items )
Debio 0617
( 2 items )
Moapar® - Salvacyl®
( 5 items )
Other News
( 54 items )
